Atara Biotherapeutics, Inc. (LON:0HIY)

Market Cap	32.39M
Revenue (ttm)	74.94M
Net Income (ttm)	-99.35M
Shares Out	n/a
EPS (ttm)	-16.86
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,628
Average Volume	5,172
Open	7.60
Previous Close	7.60
Day's Range	7.08 - 7.85
52-Week Range	0.20 - 7.87
Beta	n/a
RSI	36.36
Earnings Date	Feb 7, 2025

About Atara Biotherapeutics

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as we...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2012
• Employees: 225
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HIY

Financial Performance

In 2023, Atara Biotherapeutics's revenue was $8.57 million, a decrease of -86.51% compared to the previous year's $63.57 million. Losses were -$276.13 million, 20.9% more than in 2022.

Financial numbers in USD